2026 · 1st Quarter (Jan 1 - Mar 31)

CARIS SCIENCE INC

Filed by SPLITOAK STRATEGIES LLC.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: May 4, 2026
Income: $40,000.00
Expenses: Not reported
Registrant: SPLITOAK STRATEGIES LLC
Client: CARIS SCIENCE INC
Filing UUID: eab58cc6-08bc-42fe-ad60-5cb9f386efb4
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act; HR 7148 the Consolidated Appropriations Act of 2026; updated timing of reporting under PAMA

Literal federal measure citations: HR 5269, HR 7148

HCR · Health Issues

Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.